GENETIC TECHNOLOGIES LIMITED — Investor Presentation 2014

Jan 7, 2014

==> picture [594 x 69] intentionally omitted <==

==> picture [594 x 69] intentionally omitted <==

ASX ANNOUNCEMENT 8 January 2014

---

US investor presentation

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached investor presentation that will be presented by its Acting Chief Executive Officer, Tom Howitt, to brokers and fund managers attending the J.P. Morgan Annual Healthcare Conference in San Francisco, California, commencing on Monday, 13 January 2014.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Tom Howitt Laura Forman (USA) Chief Executive Officer (Acting) Blueprint Life Science Group Genetic Technologies Limited +1 (415) 375 3340, Ext. 103 Phone: +61 3 8412 7000

About Genetic Technologies Limited

Genetic Technologies was an early pioneer in recognizing important new applications for “non‐coding” DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non‐coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out‐licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com .

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Genetic Technologies presents: Breast Cancer Risk. Corporate Overview An Emerging Market Segment.

==> picture [721 x 46] intentionally omitted <==

==> picture [721 x 42] intentionally omitted <==

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

• Revenue-generating global diagnostics business focused on women’s health

• TM

• � Lead product is breast cancer risk test BREVAGen for non-familial (sporadic) breast cancer

• Launched mid-2011 and now approved and available in all 50 U.S. states

• U.S. CLIA approved and CE Mark awarded

� Headquartered in Melbourne, Australia

• Leveraging over 20 years of experience as the region’s largest genetic testing business

• Globally certified laboratory (CLIA, ISO, RCPA, NATA)

• Sustainable cash flow provides operational base for new asset expansion

• IP out-licensing program generates recurring revenue stream

• Approx. 77 licenses covering “non-coding DNA” granted to date, generating >$73 million in revenue

• Protected by extensive patent portfolio in 24 countries worldwide

• U.S. subsidiary, Phenogen Sciences Inc., focused on BREVAGen sales and marketing

• Established in 2010 to serve as platform for U.S. expansion within women’s health

• Headquartered in Charlotte, North Carolina

• Manages U.S. sales and marketing of BREVAGen

• BREVAGen acquired from Perlegen Sciences Inc. in 2010 as a blood-based test

• Test adapted by Phenogen into buccal (cheek) swab used today to improve patient compliance, efficiency and cost effectiveness

• BREVAGen growth and broader U.S. business development supported by legacy genetic testing business and ongoing IP out-licensing program

• Enables potential for related MDx acquisitions to leverage established sales infrastructure

• Mark Ostrowski, U.S.-based SVP, Sales and Marketing, appointed in September 2012

• 11 years at Myriad Genetics, including Head of Sales Operations

Technical and corporate support with laboratory globally certified to ISO, RCPA, NATA and CLIA

Sales and marketing, customer support, reimbursement management and sample accessioning to Laboratory Information Management System in Australia

� U.S. Operations

• TM

• • BREVAGen revenue

• Historically accounted for on a cash basis – to move to accruals basis in respect of FY 2014

• Claims received from private insurers

• Patient Protection Program provides agreed lower limit for revenue per test

� Australian Operations

• Heritage businesses (Asia Pacific) includes Medical, Parentage, Canine and Forensics testing

• Annual revenue: $3 million - $4 million

• Mature businesses with scope for modest growth

• Out-licensing

• Variable, but significant, annual revenue: $2.5 million to $13.7 million over past 5 years

• Long-term annual average revenue in excess of $6.5 million

• $4.8 million in FY 2013, up 89% on previous financial year

• Numerous potential licensees (some with large infringement) being pursued

BREVAGen TM

• BREVAGen is a simple swab-based test that can help determine a woman’s risk of developing breast cancer

• Genetic risk is combined with clinical risk from the Breast Cancer Risk Assessment Tool (BCRAT) to provide an integrated risk score

• Molecular panel of 7 SNPs (single nucleotide polymorphisms) identified from the Human Genome Project

• Each SNP is independently associated with estrogen receptor positive (ER+) sporadic breast cancer

• Over 75% of all Sporadic Breast Cancer is Estrogen Receptor Positive

• Found in 25% to 50% of women, these SNPs are high frequency/low penetrance alleles

• First test of its kind to be clinically validated to assess both five-year and lifetime risk for sporadic, hormone-dependent breast cancer

• Validated and CLIA-approved for use in caucasian women of European descent, aged ≥ 35

Mealiffe ME, et al . (2010). J Natl Cancer Inst. 102(21): 1618-1627

Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information

• Confirms the validity of combining SNP genotypes with the Gail model and demonstrates the utility of reclassification analysis for predictive risk tests.

Comen E, et al . (2011). Breast Cancer Res Treat. 127: 479-487

Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCAnegative women

• Provides independent confirmation of the validity of combining SNP genotypes with the Gail model. Demonstrates the clinical utility of improved risk assessment for guiding MRI screening and Tamoxifen chemoprevention.

Dite GS, et al . (2013). Breast Cancer Res Treat. 139(3): 887-896

Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model

• Extends reclassification of breast cancer risk using SNP genotypes to a wider population age group.

• Folse H, et al . (2013). Cancer Prev Res. 6(12):1328-36 Cost-effectiveness of a genetic test for breast cancer risk

• Simulated clinical trial demonstrates that use of BREVAGen™ to recommend MRI screening is most cost-effective

• 1 U.S. woman in 8 will develop breast cancer in her lifetime

• 39,500 of these women will die each year

• HOWEVER, with early detection, >95% of these women can survive *

Breast Cancer develops before it is detected

• A total of 235,000 breast cancer cases are diagnosed each year in the U.S.

• 80% of breast cancer is “sporadic” (meaning no strong family history)

• An estimated 188,000 sporadic cases are reported each year

• BREVAGen[TM] focuses exclusively on risk for sporadic breast cancer

• Women who are BRCA negative, with no/limited family history, who may have an elevated clinical risk

• BREVAGen[TM] provides both a five-year and lifetime percentage risk of developing sporadic breast cancer

• Allows physicians to recommend a personalized ‘Breast Health Plan’ outlining better surveillance strategies and proactive changes, tailored to each patient’s lifestyle and health status

• Provides medical management options based on independent guidelines from the American Cancer Society and ASCO (last updated 2009)

• Traditionally, a patient’s risk of sporadic breast cancer has been identified by using clinical factors alone

• Historically known as the GAIL score, Breast Cancer Risk Assessment Tool (BCRAT) measures a woman’s hormonal and reproductive risk factors, including:

• Pregnancy history

• Current age

• Age at menarche

• Age at menopause

• Race/ethnicity

� Low-risk alleles are predictive of estrogen receptor positive (ER+) tumor types and account for the majority breast cancer incidence � More than 80% of breast cancer incidence is sporadic � 75% of sporadic breast cancer is ER+

• Early detection of breast cancer is the key to successfully fighting it

• BREVAGen enables more accurate selection of patients for MRI screening

• Only 53% of women maintain regular mammographic screening *

• BREVAGen[TM] helps solve the over/under use of the mammography debate by tailoring the right schedule for the right risk profile

• USPSTF (April 2013) recommends the use of tamoxifen / raloxifene in high risk women

• BREVAGen provides a more accurate five-year risk assessment

• Recent legislation requires MD to notify patient of

1. Improved Health Outcomes

1. Improved Cost Effectiveness

when intervention and surveillance are appropriately applied to women at higher risk

There is limited, if any, real competition to BREVAGen, which includes:

• deCODE (Iceland)

• Launched in October 2008 by deCODE Genetics, but with no validation

• deCODE Breast Cancer test assesses risk based on 16 common SNPs, ordered only via MDs

• Emerged from Chapter 11 in April 2010 as a private company – purchased by Amgen in December 2012, primarily for companion diagnostics assets

• InterGenetics (Oklahoma City)

• Breast cancer test is based on 22 SNPs, but with no relevant validation

• Limited sales and marketing presence

• Self generated regulatory difficulties

• Other (largely direct to consumer)

• Navigenics (FDA warning letter received and test subsequently withdrawn from the Market)

• 23&Me (FDA warning letter received and test subsequently withdrawn from the Market)

Knome

• Women meeting the criteria below may be appropriate candidates for BREVAGen:

• Age ≥ 35 years

• Caucasian (based on current test)

• Gail-model appropriate

• Other clinical risk factors

• BREVAGen is appropriate for women who return a negative breast biopsy result = 1.3 million each year

• BREVAGen is most appropriate, and most cost effective, for women of above average clinical lifetime risk

• (10.3% of women are in this category at age 50)

• = 7.5 million women each year (including those with a negative biopsy result)

BREVAGen Samples Received By quarter (launch to end of December 2013)

==> picture [665 x 294] intentionally omitted <==

----- Start of picture text -----

1200
1125
1000
914
800
599
600
368 403
400
178
200
142
113
78 84
0
----- End of picture text -----

• Program now expanded to 23 Key Opinion Leaders (KOLs) with the objective to:

• Highlight the utility and value of BREVAGen in the clinical setting

• Provide templates for clinic adoption, patient selection and logistics

• Drive increased adoption of the BREVAGen test

� High prescribing users and KOLs on TV aim to:

• Introduce BREVAGen to the general public

• Integrate PR with new speakers in the various sales territories

� BREVAGen now available in all 50 U.S. states

• Sales force expansion:

• Current number of sales reps: 15

• Plan to add a further 3 sales reps in the first half of calendar 2014 (one in New York City, one in Colorado/Utah and one in Minnesota/Nebraska)

• Plan to add a further 3 sales reps in the second half of calendar 2014

• Plan to add a further 6 sales reps in the 2015 calendar year, taking the total to 27

• Targeting OBGYNs and breast centers

• Patients with above average clinical risk (7.5 million women at age 50 annually)

• Patients with negative breast biopsies (estimated at 1.3 million annually)

Western Region (7 reps)

• Seattle

• Dallas

• Houston

• Chicago

• Southern California

• Missouri/Kansas

• Northern California / Nevada

Eastern Region (8 reps)

• New England

• Northeast

• Ohio / Michigan

• DC / MD / VA

Florida

• New Jersey

• New York City

BREVAGen[TM] Sample Number Projections Actual Forecast

8000 7000 6000 5000 4000 3000 2000 1000

• In January 2013, there were material changes to the reimbursement process:

• Coding changes impacted all genetic / MDx testing in the U.S.

• Transition from “code stack” to “miscellaneous” CPT code

• Denials and follow-on appeals have since increased, but with strong PPO contracting and increased list price, average reimbursement for closed cases has increased by 55% (calendar 2013 vs. 2012)

• Percentage of cases written off has decreased by 61% (calendar 2013 vs. 2012)

• As sample numbers received increase, proportionately more cases are awaiting reimbursement

• Recent meeting held with primary payers (insurers) seeking input for definition of clinical utility and supporting study design and output. Planning for study is now underway

• Genetic Technologies is focused on conducting additional studies to generate additional peer-reviewed data to strengthen “clinical utility” evidence for payer contracting, leading to faster and better payment outcomes

==> picture [720 x 446] intentionally omitted <==

----- Start of picture text -----

Reimbursement Improvement – Actions Being Taken
Additional studies to include: Clinical Utility Studies to drive Claim denials due to
• MRI and/or Tamoxifen therapy “Experimental and Investigational”
Hispanic American
•
African American
•
Expanded SNP panel
Inclusion of BREVAGen in
Experimental and Investigational
NCCN Committee Guidelines
appeals package submitted
Contract directly with large
Self-Insured Employer Groups
Contract directly with Insurers
Contracting with PPOs Patient Protection Program
underpins revenue received
----- End of picture text -----

BREVAGen 1.0: 7-SNP assay, available to caucasians only

• Caucasian population in the U.S. is 62%

• Recent advances in genetics need to be included

Plan to develop and launch BREVAGen 2.0 by third quarter of calendar 2014

• Expanded panel for caucasian women

• Risk assessment panel for African-American women

• Risk assessment panel for Hispanic American women

• Collaborators and protocols have been designed

• Initial case control study to include additional ethnicities and more SNPs is now underway

Corporate Summary

• Alison J. Mew, Chief Executive Officer (currently on Personal Leave)

• Appointed CEO in December 2012

• Background in operations management in the biopharmaceutical industry in Australia and overseas, covering animal and human health

• Over 13 years with CSL Ltd. in senior positions

• Thomas G. Howitt, Chief Financial Officer and Acting CEO

• Appointed CFO in June 2004

• Wide financial experience in Australia and U.S., including key roles in the raising of bank debt and equity capital

• Currently also serving as Acting CEO

• Richard Allman, PhD, Scientific Director

• Over 20 years of scientific and research experience in the UK and Australia

• Most recently responsible for providing scientific and technical guidance for the launch of the BREVAGen™ risk assessment test to the US market and managing associated research programs

• Academic career encompassed oncology research, drug development and assay design, with a particular interest in the linkage between onco-genetic profile and treatment response

• Mark J. Ostrowski, Senior Vice President Sales and Marketing – Phenogen Sciences Inc.

• Appointed Senior Vice President Sales and Marketing – Phenogen Sciences Inc. in September 2012

• More than 20 years of sales and marketing experience in molecular diagnostics (including Director of Sales Operations at Myriad Genetics (NASDAQ: MYGN) and Director of Managed Care Services at DIANON Systems

• Academic tenure in the specialized molecular diagnostics space and led successful commercialization and clinical

• Seven new licenses granted during the 2013 financial year, totalling 77 to date

• More than $73 million in gross revenues generated from licensing to date

• U.S. assertion program continues in earnest, with 10 cases of infringement underway, including three against Big Pharma (Pfizer, GSK and BMS)

• New assertion cases focusing of “762” mapping patent to extend the life of the licensing program

• European targets being independently pursued by Genetic Technologies

• Third re-exam of “179” patent successfully defended

• Goal to continue to deliver valuable non-dilutive funding to the Company

(AUD millions) Revenue / gains Operations Licensing Net profit / (loss) Cash (refer note)	2013 1.1 1.0 0.1 (2.6) 1.8	2012 1.4 1.0 0.3 (2.5) 6.7

Subsequent to September 30, the Company raised a further AUD 9.6 million from the issue of shares and convertible notes

Shares outstanding 581.4 million ADRs (@30:1 ratio) 19.4 million Top 20 shareholders 69.7% Total shareholders 2,903 Options outstanding 10.8 million (employees only)

Market cap (@ $0.06) AUD 35 million

• Maintain focus on expansion of U.S. operations

• Increase U.S. sales force to cover all major U.S. sales territories

• Complete and launch “second generation” BREVAGen[TM] test to improve performance and increase market acceptance in the U.S.

• Broaden available ethnicities to expand available markets

• Aim to exceed 10,000 BREVAGen samples in the 2014 calendar year

• Work with payers (insurers) to improve reimbursement outcomes

• Ensure adequate funding is available to meet objectives

• Maximize value from licensing, heritage business and the commercialization of

Tom Howitt Acting CEO Genetic Technologies Limited Phone +61 3 8412 7000 Email info@gtglabs.com